Management of Atopic Dermatitis During the COVID-19 Pandemic: Key Questions and Review of the Current Evidence

Po Chien Wu*, Chia Lun Li, Yun Ting Chang, Chih Chiang Chen, Chen Yi Wu, Sheng Hsiang Ma*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Abstract: Since the outbreak of COVID-19, management of atopic dermatitis (AD) has been widely discussed. Key issues include the risk of COVID-19 infection and related outcomes in AD patients, the efficacy and safety of COVID-19 vaccination in AD populations, and management of AD in the COVID-19 pandemic. Recent studies have shown that patients with AD have a slightly increased risk of COVID-19 infection but are not associated with a worse outcome than the non-AD population. COVID-19 vaccination is generally effective and safe in patients with AD. However, temporary discontinuation of certain systemic immunomodulatory agents after vaccination is suggested. During the pandemic, continuation of all immunomodulating agents is suggested, but these agents should be paused when patients with AD are infected with COVID-19 until recovery. Further studies are warranted to investigate the long-term interaction between AD and COVID-19 to aid clinical decisions during the pandemic.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalDermatitis
Volume34
Issue number2
DOIs
StatePublished - 1 Mar 2023

Fingerprint

Dive into the research topics of 'Management of Atopic Dermatitis During the COVID-19 Pandemic: Key Questions and Review of the Current Evidence'. Together they form a unique fingerprint.

Cite this